2-Bromo-6-nitrophenol

We are 2-Bromo-6-nitrophenol CAS:13073-25-1 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:2-Bromo-6-nitrophenol
CAS.NO:13073-25-1
Synonyms:2-Bromo-6-nitrophenol
2-Brom-6-nitro-phenol
6-Nitro-2-bromophenol
2-bromo-6-nitro-phenol
Phenol,2-bromo-6-nitro
 
Physical and Chemical Properties:
Density 1.9±0.1 g/cm3
Boiling Point 227.2±20.0 °C at 760 mmHg
Melting Point 66-70 °C(lit.)
Molecular Formula C6H4BrNO3
Molecular Weight 218.005
Flash Point 91.2±21.8 °C
Vapour Pressure 0.1±0.5 mmHg at 25°C
Index of Refraction 1.652
 
Specification:
Appearance:White to yellow crystalline powder
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Eltrombopag(CAS:496775-61-2).

2-Bromo-6-nitrophenol


Related News: The Company’s immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs).4-methylsalicylic acid The rigosertib Pre-approval Access Program is expected to launch in first half of 2020 and will allow Inceptua to supply intravenous rigosertib within designated countries, primarily and initially concentrated in selected countries in Europe, in response to physician requests for patients with higher-risk MDS who have exhausted all available treatment options, and are not eligible for or have no access to the INSPIRE study.944801-28-9 The rigosertib Pre-approval Access Program is expected to launch in first half of 2020 and will allow Inceptua to supply intravenous rigosertib within designated countries, primarily and initially concentrated in selected countries in Europe, in response to physician requests for patients with higher-risk MDS who have exhausted all available treatment options, and are not eligible for or have no access to the INSPIRE study.Ácido (2-metoxinaftalen-1-il) borónico CAS:104116-17-8 The rigosertib Pre-approval Access Program is expected to launch in first half of 2020 and will allow Inceptua to supply intravenous rigosertib within designated countries, primarily and initially concentrated in selected countries in Europe, in response to physician requests for patients with higher-risk MDS who have exhausted all available treatment options, and are not eligible for or have no access to the INSPIRE study.The rigosertib Pre-approval Access Program is expected to launch in first half of 2020 and will allow Inceptua to supply intravenous rigosertib within designated countries, primarily and initially concentrated in selected countries in Europe, in response to physician requests for patients with higher-risk MDS who have exhausted all available treatment options, and are not eligible for or have no access to the INSPIRE study.

Related Products
Product Name
methyl cyanoacetate View Details
DL-Homocysteinethiolactone hydrochloride View Details
2,3-Dimethyl-2H-indazol-6-amine View Details
3-Diethylaminopropylamine manufacturer Nα-t-butoxycarbonyl-L-asparagine manufacturer 4-Fluoro-2-(trifluoromethyl)phenol manufacturer 2-Pipecoline manufacturer N-[(9H-Fluoren-9-ylmethoxy)carbonyl]glycylglycylglycylglycine manufacturer